



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 Aug 2022 (#32)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-OD-22-195](#) New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023. This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after January 25, 2023.

The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Plan Form
- PHS 398 Career Development Award Supplemental Form
- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form

For NIH, as part of the implementation of the 2023 NIH Data Management and Sharing Policy, a new "Other Plan(s)" attachment field has been added to the PHS 398 Research Plan Form and the PHS 398 Career Development Award Supplemental Form. Applicants must attach the required Data Management and Sharing Plan in this new field in

FORMS-H applications. See [NOT-OD-21-013](#) and [NOT-OD-22-189](#) for more information. Note: Although the 2023 NIH Data Management and Sharing Policy is not applicable to fellowship and institutional training grant applications, the new attachment field was added for potential future use with other plans.

[NOT-OD-22-189](#) Implementation Details for the NIH Data Management and Sharing Policy. The purpose of this notice is to inform the extramural research community of implementation details for the [NIH Policy for Data Management and Sharing \(DMS Policy\)](#) affecting grant and cooperative agreement applications submitted for receipt dates on or after January 25, 2023. The specific changes to competing grant and cooperative agreement application instructions clarified below will be implemented with application form packages identified with a Competition ID of “FORMS-H” and incorporated into the forthcoming FORMS-H application guides. Although the DMS Policy will apply also to Research and Development (R&D) contracts, NIH intramural research projects, and other funding agreements (e.g., Other Transactions), the forms changes and other implementation details provided in this Notice apply only to NIH extramural grant and cooperative agreement activities. Details applicable to R&D contracts will be incorporated into the appropriate Requests for Proposals, and details applicable to Other Transactions will be incorporated into the appropriate Research Opportunity Announcement.

[NOT-OD-22-190](#) Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022. This notice informs the community of NIH and AHRQ application due date adjustments to accommodate scheduled federal system downtime. Grants.gov has a planned production system outage from Friday, September 23, 2022 at 12:01 AM ET to Thursday, September 29, 2022 at 11:59 PM ET (see [Grants.gov calendar](#)). Grants.gov will use this time to migrate their services to the Cloud. In response, NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

[2022-2023 NIH Climate and Health Scholars Program](#): This new program seeks to bring climate and health focused scientists from outside the U.S. federal government to work with NIH staff and build climate and health capacity. Applications due: 15 September. U.S. or international scientists from the academic or private sectors. Candidates (Ph.D. or M.D.) can be early career to senior scientists and should have a strong publication record in climate science or climate and health sciences: including basic, clinical, translational, population, social/behavioral, and/or implementation sciences. Candidates need not have an NIH funding record.

[NOT-HD-22-041](#) Notice of Pre-Application Webinar for the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN) Funding Opportunity Announcements. This Notice provides information regarding the upcoming Pre-Application Webinar for the recently published *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Funding Opportunity Announcements (FOAs) entitled Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN): [RFA-HD-23-013](#) for the PATC³H-IN Clinical Research Centers (CRC) and [RFA-HD-23-014](#) for the PATC³H-IN Coordination, Translation and Advanced Methods and Analytics Center (CTAMAC).

Webinar Information for the PATC³H-IN CRC and CTAMAC FOAs

Date: September 15, 2022

Time: 9:00 - 11:00 AM ET (U.S.)

[NOT-NS-23-011](#) Notice of Information: High-Priority Principles of Rigorous Research for NINDS Materials to Enhance Training in Experimental Rigor (METER) Funding Opportunity. The [Office of Research Quality](#) at the National Institute of Neurological Disorders and Stroke (NINDS) is issuing this notice to inform the extramural research community about principles of rigorous biomedical research that have not yet been selected for development into educational units by previous awardees of the [Materials to Enhance Training in Experimental Rigor \(METER\) \(UE5 Clinical Trial Not Allowed\)](#) funding opportunity. Two receipt dates remain for METER: October 11, 2022 and October 10, 2023.

[NOT-OD-22-194](#) Review of the Accuracy of Grants Information for Fiscal Year 2022. As the fiscal year comes to an end on September 30, 2022, NIH encourages Recipient Organizations to verify the accuracy of their grant assignments to Departments or Components within Organizations of Higher Education in eRA Commons through the Grant Re-assign function. Any corrections to the data must be made by 8:00 PM EDT on Monday, October 3, 2022 to be reflected in NIH annual reports. Only the Authorized Organization Representative (AOR) or Signing Official (SO) has the authority to submit corrections for a recipient organization or investigator.

[NOT-HG-22-030](#) Notice of Intent to Publish a Funding Opportunity Announcement for Diversity Centers for Genome Research (U54 Clinical Trials Optional). The National Human Genome Research Institute, with other NIH Institutes and Centers (ICs)-- the National Institute of Mental Health and the National Institute on Minority Health and Disparities, intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish Diversity Centers for Genomic Research (DCGR) at Minority Serving Institutions (MSIs) (as defined below). Each DCGR award will support a multi-investigator, interdisciplinary team to develop 2-3 interrelated, innovative genomic research projects that address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics; ethical, legal, and social implications of genomic research; and/or genomics and health equity. Along with its scientific goals, the DCGR will expand the pool of genomic scientists, clinician scientists, and researchers from diverse backgrounds, including those from groups that are underrepresented in biomedical research, who can perform innovative genomics research by providing didactic, practicum and research activities and experiences that are aligned with the research projects. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. First Estimated Application Due Date: 29 November 2022.

[NOT-HG-22-031](#) Notice of Intent to Publish a Funding Opportunity Announcement for Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional). The National Human Genome Research Institute, with other NIH Institutes and Centers (ICs)-- the National Institute of Mental Health and the National Institute on Minority Health and Disparities, intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish Diversity Centers for Genomic Research (DCGR) at Minority Serving Institutions (MSIs) (as defined below). Each DCGR award will support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects that address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics, ethical, legal, and social implications of genomic research (ELSI); and/or genomics and health equity. The outcome of the development and feasibility studies will be fully developed plans to carry out all activities of a full-scale Diversity Center for Genome Research. Along with its scientific goals, the DCGR will expand the pool of genomic scientists, clinician scientists, and researchers from diverse backgrounds, including those from groups that are underrepresented in biomedical research, who can perform innovative genomics research by providing didactic, practicum and research activities and experiences that are aligned with the research projects. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Notice of Special Interest (NOSI)

[NOT-OD-22-166](#) Notice of Special Interest (NOSI): Research on the Health of Bisexual and Bisexual+ People. This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer. Investigators are strongly encouraged to reach out to the relevant contacts listed in the Inquiries section of this NOSI to determine whether the FOA and funding mechanism selected are appropriate for the proposed research. Expiration Date: 8 May 2025.

Funding Opportunity Announcements (FOA)

1. Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-22-019](#)

Type: U54

Application Due Date: November 08, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of the Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) Funding Opportunity Announcement (FOA) is to build implementation science centers in low- and middle-income countries (LMICs). This initiative will support implementation science research capacity-building activities, including research projects that identify, develop, and test innovative theory-based strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based cancer control interventions (e.g., programs, tools, policies, and guidelines) in LMICs. NCI will support several U54 Specialized Centers with transdisciplinary research teams meaningfully collaborating with key stakeholders (e.g., health systems, ministries of health, clinicians, and communities) that must include at least one PI or MPI from an LMIC-based institution. This initiative aims to foster LMIC-based implementation science programs to inform implementation of cancer control efforts in LMICs.

Budget: NCI intends to fund up to 4 awards, corresponding to a total of \$4 million, for fiscal year 2023. The number of awards is contingent upon the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed \$750,000 per year in direct costs. Project period of 5 years is required.

2. Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-215](#)

Type: R01

Application Due Date: October 05, 2022 through to June 05, 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.

Budget: Application budgets are limited to \$499,999 Direct Costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. AD/ABRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-221](#)

Type: R01

Application Due Date: 5 October 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that expand the use of existing data resources to drive new discoveries that can lead to better understanding of the relationship between early life social determinants of health (SDOH), adverse childhood experiences (ACEs), AD/ABRD biomarkers, and the development of cognitive impairment and dementia, especially in populations experiencing health disparities.

Budget: The NINDS has committed \$1,000,000 to fund up to two awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets should reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-223](#)

Type: R01

Application Due Date: 7 December 2022; 7 December 2023; 7 December 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and their effect on immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

5. Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-22-019](#)

Type: U01

Application Due Date: 1 November 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Data Analysis and Validation (DAV) Centers to join the new NHGRI program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase I will also assess the scale limitations of such methods, develop common data formats, establish "use cases" for this catalog, and inform whether and how a potential second phase will be implemented. The DAV Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. Other components of MorPhiC: Data Production Research and Development Centers and a Data Resource and Administrative Coordination Center have been established.

Budget: NHGRI intends to commit \$1.5M in FY {2023} to fund {2-3} awards. Application budgets need to reflect the actual needs of the proposed project but should not exceed \$350K direct cost per year. The maximum project period is for five years.

6. HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-22-070](#)

Type: R01

Application Due Date: 4 November 2022; 7 March 2023; 6 July 2023; 7 November 2023; 6 March 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability.

Budget: The NIH HEAL (Helping to End Addiction Long-term) Initiative intends to commit an estimated total of \$6 million to fund 4-5 awards in FY 2023. Awards issued under this FOA are part of funds set aside to support the NIH HEAL Initiative. Future year amounts will depend on annual appropriations. Application budgets need to reflect the actual needs of the proposed project and are limited to direct costs of \$750,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105